The possible use of the L-type calcium channel antagonist verapamil in drug-resistant epilepsy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2016-01-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14737175.2016.1121097PMID 26567612
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Drug Resistance in Cortical and Hippocampal Slices from Resected Tissue of Epilepsy Patients: No Significant Impact of P-Glycoprotein and Multidrug Resistance-Associated Proteins

  2015cited by this paper
• Role of P-Glycoprotein in Refractoriness of Seizures to Antiepileptic Drugs in Lennox-Gastaut Syndrome

  2015cited by this paper
• L-type Calcium Channel Blockers Enhance Trafficking and Function of Epilepsy-associated α1(D219N) Subunits of GABA(A) Receptors.

  2015cited by this paper
• Approaching complete inhibition of P-glycoprotein at the human blood–brain barrier: an (R)-[11C]verapamil PET study

  2015cited by this paper
• A pilot double-blind trial using verapamil as adjuvant therapy for refractory seizures.

  2014cited by this paper
• Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study.

  2014cited by this paper
• In vivo P-glycoprotein function before and after epilepsy surgery

  2014cited by this paper
• P-glycoprotein Expression and Pharmacoresistant Epilepsy: Cause or Consequence?

  2014cited by this paper
• P-glycoprotein alters blood–brain barrier penetration of antiepileptic drugs in rats with medically intractable epilepsy

  2013cited by this paper
• Adjunctive use of verapamil in patients with refractory temporal lobe epilepsy: a pilot study.

  2013cited by this paper
• The transport of antiepileptic drugs by P-glycoprotein.

  2012cited by this paper
• Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy.

  2012cited by this paper
• P‐glycoprotein imaging in temporal lobe epilepsy: In vivo PET experiments with the Pgp substrate [11C]‐verapamil

  2012cited by this paper
• A Novel Positron Emission Tomography Imaging Protocol Identifies Seizure-Induced Regional Overactivity of P-Glycoprotein at the Blood–Brain Barrier

  2011cited by this paper
• Drug-resistant epilepsy.

  2011influential reference
• Termination of refractory focal status epilepticus by the P‐glycoprotein inhibitor verapamil

  2011cited by this paper
• Add‐on treatment with verapamil in pharmacoresistant canine epilepsy

  2011cited by this paper
• In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P‐glycoprotein

  2011influential reference
• Regional P‐Glycoprotein Activity and Inhibition at the Human Blood–Brain Barrier as Imaged by Positron Emission Tomography

  2010cited by this paper
• Verapamil attenuates the malignant treatment course in recurrent status epilepticus.

  2010cited by this paper
• Assessment of Regional Differences in Tariquidar-Induced P-Glycoprotein Modulation at the Human Blood–Brain Barrier

  2010cited by this paper
• Over-expression of P-glycoprotein in the canine brain following spontaneous status epilepticus.

  2009cited by this paper
• Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy.

  2009cited by this paper
• Verapamil for Cluster Headache. Clinical Pharmacology and Possible Mode of Action

  2009influential reference
• Pharmacoresistance in Epilepsy: A Pilot PET Study with the P‐Glycoprotein Substrate R‐[11C]verapamil

  2007cited by this paper
• Region-Specific Overexpression of P-glycoprotein at the Blood-Brain Barrier Affects Brain Uptake of Phenytoin in Epileptic Rats

  2007cited by this paper
• Association of CYP3A5 Polymorphisms with Hypertension and Antihypertensive Response to Verapamil

  2007cited by this paper
• Mechanisms of drug resistance in status epilepticus

  2007cited by this paper
• The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy.

  2006cited by this paper
• Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography

  2005cited by this paper
• DIFFERENTIAL MECHANISM-BASED INHIBITION OF CYP3A4 AND CYP3A5 BY VERAPAMIL

  2005influential reference
• Drug resistance in brain diseases and the role of drug efflux transporters

  2005cited by this paper
• Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy

  2005influential reference
• Multidrug resistance in epilepsy: rats with drug-resistant seizures exhibit enhanced brain expression of P-glycoprotein compared with rats with drug-responsive seizures.

  2005cited by this paper
• Calcium‐channel Blocker Verapamil Administration in Prolonged and Refractory Status Epilepticus

  2005cited by this paper
• Use of Verapamil as a Potential P-Glycoprotein Inhibitor in a Patient with Refractory Epilepsy

  2004cited by this paper
• Drug resistance in epilepsy: expression of drug resistance proteins in common causes of refractory epilepsy.

  2002cited by this paper
• Lung cancer--management and outcome in Glasgow, 1991-92.

  1998cited by this paper
• 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein.

  1998cited by this paper
• Calcium Channel Blockers Verapamil and Nimodipine Inhibit Kindling in Adult and Immature Rats

  1994cited by this paper

• Infantile epileptic spasms syndrome: Mechanisms and therapeutic approaches.

  2025cites this paper
• Discovery of novel hybrid pyrrolidin-2-one derivatives exhibiting potent antiseizure and antinociceptive effects in preclinical models.

  2025cites this paper
• Novel Alaninamide Derivatives with Drug-like Potential for Development as Antiseizure and Antinociceptive Therapies—In Vitro and In Vivo Characterization

  2024cites this paper
• Discovery of New 3-(Benzo[b]Thiophen-2-yl)Pyrrolidine-2,5-Dione Derivatives as Potent Antiseizure and Antinociceptive Agents—In Vitro and In Vivo Evaluation

  2024cites this paper
• Discovery and Profiling of New Multimodal Phenylglycinamide Derivatives as Potent Antiseizure and Antinociceptive Drug Candidates

  2024cites this paper
• Drug-resistant epilepsy: Definition, pathophysiology, and management.

  2023cites this paper
• Diltiazem and Verapamil: Combined Experimental and Computational Approaches to Structural and Spectroscopic Characterization

  2023cites this paper
• Pharmacological diversity amongst approved and emerging antiseizure medications for the treatment of developmental and epileptic encephalopathies

  2023cites this paper
• In Vivo and In Vitro Characterization of Close Analogs of Compound KA-11, a New Antiseizure Drug Candidate

  2023cites this paper
• Altered Extracellular Matrix as an Alternative Risk Factor for Epileptogenicity in Brain Tumors

  2022cites this paper
• Ranolazine Interacts Antagonistically with Some Classical Antiepileptic Drugs—An Isobolographic Analysis

  2022cites this paper
• New Phenylglycinamide Derivatives with Hybrid Structure as Candidates for New Broad-Spectrum Anticonvulsants

  2022cites this paper
• Infantile Spasms: An Update on Pre-Clinical Models and EEG Mechanisms

  2020cites this paper
• Is cannabidiol a drug acting on unconventional targets to control drug‐resistant epilepsy?

  2020cites this paper
• Verapamil and Alzheimer’s Disease: Past, Present, and Future

  2020cites this paper
• Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells

  2020cites this paper
• Interactions of antiepileptic drugs with drugs approved for the treatment of indications other than epilepsy

  2020cites this paper
• Recent advances in treatment of epilepsy-related sodium channelopathies.

  2019cites this paper
• Verapamil and Cluster Headache: Still a Mystery. A Narrative Review of Efficacy, Mechanisms and Perspectives

  2019cites this paper
• Comorbidity between epilepsy and cardiac arrhythmias: Implication for treatment.

  2019cites this paper
• Long Non-coding RNA KCNQ1OT1 Contributes to Antiepileptic Drug Resistance Through the miR-138-5p/ABCB1 Axis in vitro

  2019cites this paper
• Verapamil as an Adjuvant Treatment for Drug-Resistant Epilepsy

  2018cites this paper
• MicroRNA-298 Reverses Multidrug Resistance to Antiepileptic Drugs by Suppressing MDR1/P-gp Expression in vitro

  2018cites this paper
• Clinical reappraisal of the influence of drug-transporter polymorphisms in epilepsy

  2018cites this paper
• Antiepileptic drugs: progress and development

  2018cites this paper
• Lovastatin suppresses hyperexcitability and seizure in Angelman syndrome model.

  2018cites this paper
• Development of new antiepileptic drug candidates: a set of lamotrigine-related compounds

  2018cites this paper
• Emerging drugs for the treatment of Dravet syndrome

  2018cites this paper
• Evaluation of Compatibility and Stability of a Novel Anticonvulsant Enaminone Compound with Common Tableting Excipients

  2017cites this paper
• Novel Hybrid Anticonvulsants Derived from Pyrrolidine-2,5-dione Scaffold with Broad Spectrum of Activity in the Preclinical Studies.

  2017cites this paper
• Verapamil-induced breakdown of the blood–brain barrier presenting as a transient right middle cerebral artery syndrome

  2017cites this paper
• Outside the box: Medications worth considering when traditional antiepileptic drugs have failed.

  2017cites this paper
• A case of refractary epilepsy and related pain due to dysmenorrhea solved with loading dose of lacosamide: clinical and neurophysiological correlates

  2017cites this paper
• Verapamil Blocks Scopolamine Enhancement Effect on Memory Consolidation in Passive Avoidance Task in Rats

  2017cites this paper
• Low dose verapamil as an adjunct therapy for medically refractory epilepsy - An open label pilot study.

  2016cites this paper
• Design, synthesis and anticonvulsant activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and -butanamides.

  2016cites this paper